Carna Biosciences, Inc.
4572.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.25 | -0.04 | 0.49 |
| FCF Yield | -25.83% | -19.26% | -11.78% | -11.28% |
| EV / EBITDA | -1.55 | -5.55 | -3.12 | -21.03 |
| Quality | ||||
| ROIC | -80.55% | -27.24% | -31.89% | -10.85% |
| Gross Margin | 73.20% | 89.22% | 87.63% | 93.29% |
| Cash Conversion Ratio | 0.63 | 1.48 | 0.54 | 2.89 |
| Growth | ||||
| Revenue 3-Year CAGR | -22.87% | -6.94% | 6.96% | -14.32% |
| Free Cash Flow Growth | 17.83% | -102.42% | 47.13% | -18.68% |
| Safety | ||||
| Net Debt / EBITDA | 0.96 | 2.48 | 2.40 | 6.43 |
| Interest Coverage | -701.86 | -323.67 | -239.15 | -135.32 |
| Efficiency | ||||
| Inventory Turnover | 1.11 | 1.25 | 1.45 | 1.23 |
| Cash Conversion Cycle | 375.60 | 466.25 | 296.03 | 516.72 |